Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
32.67
-0.62 (-1.86%)
Sep 1 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 32.41 - 33.55
52 week 19.31 - 36.20
Open 32.80
Vol / Avg. 394,402.00/279,344.00
Mkt cap 1.29B
P/E 51.67
Div/yield     -
EPS 0.63
Shares 38.80M
Beta 1.13
Inst. own 83%
Nov 4, 2015
Q3 2015 Emergent BioSolutions Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 27, 2015
Emergent BioSolutions Inc at Three Part Advisors Midwest IDEAS Investor Conference
Aug 6, 2015
Q2 2015 Emergent BioSolutions Inc Earnings Release
Aug 6, 2015
Emergent BioSolutions Proposed Spin-off of BioSciences Business & Q2 2015 Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 11.18% 8.16%
Operating margin 17.01% 12.90%
EBITD margin - 20.11%
Return on average assets 6.08% 4.67%
Return on average equity 10.28% 7.05%
Employees 1,280 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company's two operating divisions include Biodefense and Biosciences. The Company's Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense division's marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences division's marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Daniel J Abdun-Nabi President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer
Age: 57
Bio & Compensation  - Reuters
Adam Havey Executive Vice President and President - BioDefense Division
Age: 44
Bio & Compensation  - Reuters
Barry A. Labinger Executive Vice President, President - Biosciences Division
Age: 51
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 63
Bio & Compensation  - Reuters
George A. Joulwan Independent Director
Age: 75
Bio & Compensation  - Reuters